Lentiviral vectors and AAV vectors are both produced using viral packaging systems, both rely heavily on transient transfection of HEK293 cells, and both require multi-step downstream purification before they can be used as drug products. These surface similarities lead some developers — particularly those with experience in one platform transitioning to the other — to underestimate how different the two manufacturing processes actually are. The differences are not incremental. They reflect fundamentally different physical properties, stability profiles, and downstream processing requirements that demand distinct infrastructure, analytical methods, and quality control strategies.
The Physical Difference That Drives Everything
The single most consequential manufacturing difference between lentiviral and AAV vectors is structural: lentiviral vectors are enveloped, and AAV vectors are not.
The lentiviral vector particle is surrounded by a lipid bilayer membrane derived from the producer cell’s plasma membrane. This envelope is acquired as the newly assembled viral core buds through the cell membrane during particle release. The envelope typically incorporates the VSV-G glycoprotein — a protein from vesicular stomatitis virus that provides broad cell tropism and stability — as the primary surface protein mediating cell entry.
AAV, by contrast, is a non-enveloped virus. Its icosahedral protein capsid is directly exposed to the external environment, with no lipid membrane surrounding it. This naked protein shell is physically robust: it tolerates a range of temperatures, survives freeze-thaw cycles without significant loss of activity, and maintains integrity under the shear forces encountered in standard bioprocessing equipment.
The lentiviral envelope is fragile by comparison. Lipid membranes are susceptible to mechanical disruption from shear stress, freeze-thaw cycles, temperature fluctuations, and prolonged storage at suboptimal conditions. Lentiviral particles have a significantly shorter bench-top stability and are more sensitive to processing conditions than AAV. This fragility has manufacturing consequences at every step from harvest through formulation.
Upstream Production: Similarities and Differences
Both platforms most commonly use transient transfection of HEK293 cells as the primary upstream production method. For AAV, the three-plasmid system delivers the transfer, Rep-Cap, and helper plasmids simultaneously. For lentiviral production, a four-plasmid system is typical: a transfer plasmid carrying the therapeutic transgene flanked by lentiviral long terminal repeats, a packaging plasmid encoding the HIV-derived Gag and Pol proteins, a Rev plasmid encoding the Rev regulatory protein, and an envelope plasmid encoding VSV-G.
VSV-G presents a specific challenge in lentiviral manufacturing: it is cytotoxic to producer cells at high expression levels. This toxicity limits the duration over which cells can produce vector and contributes to the narrower harvest window for lentiviral vectors compared to AAV. Strategies to manage VSV-G cytotoxicity include inducible promoter systems that allow VSV-G expression to be switched on at the optimal time point during production, and stable producer cell lines in which VSV-G is under inducible control.
Lentiviral vectors are released from producer cells by budding — a continuous process during which particles accumulate in the culture supernatant. This means that lentiviral production can begin as soon as the transfection is active and continues until the cells lose viability. Harvest is typically performed 48 to 72 hours post-transfection, balancing maximum vector accumulation in the supernatant against cell viability decline. The supernatant is the primary harvest material.
AAV production also occurs primarily in the 72 to 96 hours following transfection, but AAV particles accumulate inside the producer cells as well as in the supernatant. Depending on the production platform, harvest may require cell lysis to release intracellular particles, followed by clarification to remove cell debris before downstream processing.
Downstream Processing: Divergent Approaches
The downstream processing trains for lentiviral and AAV vectors differ substantially, driven by the physical properties of the two particle types.
For lentiviral vectors, the primary downstream challenges are concentration, removal of process-related impurities, and preservation of particle integrity during processing. The lentiviral particle’s fragility means that each processing step must be optimized not only for impurity removal but for minimal mechanical and thermal stress on the vector. Tangential flow filtration (TFF) is commonly used for concentration and buffer exchange and is preferred over centrifugation-based approaches at scale because it applies lower shear forces. Ion exchange chromatography is used for purification but must be performed under conditions that preserve envelope integrity. The total number of unit operations must be minimized relative to what might be used for a more physically robust product, because each step introduces the opportunity for envelope damage and vector loss.
For AAV, the non-enveloped capsid tolerates a wider range of processing conditions. Density gradient ultracentrifugation using cesium chloride or iodixanol was the early standard for AAV purification and remains in use for research and early clinical material, effectively separating full capsids from empty capsids based on buoyant density. For clinical and commercial manufacturing, column chromatography — affinity chromatography using AAV-specific affinity resins followed by ion exchange polishing — has become the preferred approach due to its scalability, reproducibility, and compatibility with GMP requirements. AAV can withstand the binding, washing, and elution conditions used in chromatographic purification without the envelope-integrity concerns that constrain lentiviral processing.
Stability and Cold Chain
Lentiviral vectors are stored at -80°C and have limited stability at higher temperatures. The cold chain requirements for lentiviral products are stringent, and cold chain excursions — temperature deviations during transport or storage — are a known source of potency loss that must be monitored and characterized. The functional titer of a lentiviral preparation decreases over time even under optimal storage conditions, and stability studies must demonstrate adequate potency retention over the intended shelf life.
AAV is considerably more thermostable. Approved AAV gene therapies are typically stored frozen but have demonstrated stability at refrigerator temperatures (2 to 8°C) for extended periods, and some programs have achieved room-temperature stability sufficient for short-term handling. This stability profile reduces cold chain complexity and is one of the practical advantages of AAV for programs requiring broad distribution or administration in resource-limited settings.
Analytical Characterization
The analytical methods used to characterize lentiviral and AAV products reflect their different physical structures and critical quality attributes.
Lentiviral potency is assessed by functional transduction assay — measuring the ability of the vector to transduce a target cell line and express the transgene, typically quantified by the number of integrated copies per cell or by expression of a marker gene. Because lentiviral particles do not have a genome titer measurement as directly interpretable as AAV viral genome titer, the relationship between physical particle count and functional titer is a critical characterization parameter. The ratio of physical particles (p24 antigen-based particle counting) to functional titer (transducing units per mL) defines the specific activity of the preparation and is used to monitor process consistency.
AAV characterization includes viral genome titer by digital PCR, total capsid titer by ELISA or similar immunoassay, full/empty capsid ratio by analytical ultracentrifugation or equivalent method, identity by capsid sequencing and transgene sequencing, potency by in vitro transduction assay or relevant biological activity assay, and sterility, endotoxin, and mycoplasma testing. The full/empty ratio is a critical quality attribute specific to AAV with no direct lentiviral equivalent.
Choosing the Right Manufacturing Infrastructure
The manufacturing infrastructure required for lentiviral and AAV production overlaps in some respects — both require BSL-2 containment, HEK293-compatible bioreactors, GMP-compliant cleanrooms, and comprehensive analytical capability — but diverges in the specific equipment, process design, and stability management requirements that reflect each platform’s physical properties.
Organizations building gene therapy manufacturing capability for the first time should resist the assumption that expertise in one vector platform transfers directly to the other. The process development principles are related, but the specific knowledge required to reliably produce a high-titer, high-purity, GMP-compliant lentiviral or AAV product is platform-specific. Programs that underestimate this distinction early in development tend to encounter manufacturing problems at exactly the stage — IND-enabling studies, first-in-human manufacturing — when delays are most costly.